An analysis of current measles vaccination program in the eastern Chinese province of Zhejiang (which provides 1 dose of measles-rubella vaccine at 8 months of age and 1 dose of MMR at 18 months) estimated that, for every dollar spent on immunization, the health system saves $6.06 in treatment costing, including the costs of treating complications and long-term sequelae, such as hearing loss.
According to a systematic review and meta-analysis, children who are rural-urban migrants in China, India and Nigeria were less likely to be fully-immunized by the age of one year than non-migrant urban residents and the general population. These inequities in vaccination rates — often concealed in national averages — call for special efforts to improve immunization rates in this rapidly growing sub-population to reduce both health inequities and the risk of infectious disease outbreaks in the wider society.
Children in Shanghai, China whose families migrated from rural areas — now roughly 40% of the city’s total population — are half as likely as “local” children to receive the first dose of measles vaccine by 9 months of age and 42% less likely to receive the second measles dose by 24 months. The lower rates of timely first dose measles vaccination among rural migrants vs. local children — 78% vs. 89% – – are a key obstacle to measles elimination in China. This indicates a need to specifically target non-local children for vaccination, especially those living in primarily migrant communities.
If China — one of the few remaining countries in the world that haven’t introduced Hib vaccine in their national immunization program — decides to include the vaccine in their program, it could actually be cost saving; the vaccination costs would be less than the averted costs of illness from Hib meningitis and pneumonia, if a vaccine price matching UNICEF’s (US$2/dose) can be obtained. The vaccination will be cost-effective, but not cost saving, if the program pays the current market price in China of US$10 per dose.
Children born to North Korean refugee women in China have much lower vaccination rates than local Chinese or migrant children — with full immunization rates of 14% compared to 93% for local ethnic Chinese children and 55% for migrant children. While all ethnic Chinese children are registered and provided with free vaccinations and there are specific programs targeting migrant children, children born to Korean refugees have no legal status and are thus excluded from the public health care system.
According to a study using local epidemiological data in China, vaccinating infants with pneumococcal conjugate vaccine (PCV-13), using a 3+1 schedule, would prevent more than 10 times as many deaths from invasive pneumococcal disease and pneumonia in unvaccinated individuals (147,500 per year) than it would prevent directly in those vaccinated (12,800 per year). This would be due mainly to a reduction in hospitalizations for pneumonia.
The cost-effectiveness of vaccinating infants with PCV-13 in China was estimated to be 21 times greater when the indirect effects of vaccination in reducing invasive pneumococcal disease and hospitalized cases of pneumonia in older (unvaccinated) individuals was taken into account — with costs per quality of life-year gained (QALY) of around US$564 (Y3,777) vs. $11,836 (Y79,204) when only the direct impact on vaccinated children is considered.
In a systematic review of qualitative research from low- and middle-income countries, women’s low social status was shown to be a barrier to their children accessing vaccinations. Specific barriers included access to education, income, resource allocation, and autonomous decision-making related to time. The authors suggest that expanding the responsibility for children’s health to both parents (mothers and fathers) may be one important element in removing persistent barriers to immunization often faced by mothers.